WithdrawnPhase 2

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Stopped: Business decision

0Started 2017-04

Plain-language summary

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

Who can participate

Age range18 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of WHO Group 3 PH associated with COPD
✓. Subjects are required to have a right heart catheterization (RHC) within one year prior to the first dose of study drug with the following parameters:
✓. Pulmonary vascular resistance (PVR) ≥ 4 Wood Units (WU) and
✓. A left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) of ≤ 12 mmHg if PVR ≥ 4 WU to \< 6.25 WU or ≤ 15 mmHg if PVR ≥ 6.25 WU and
✓. A mean pulmonary arterial pressure (mPAP) of ≥ 30 mmHg
✓. Clinical Diagnosis of COPD will be made using accepted Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria, including Baseline spirometry with the following documented parameters:
✓. FEV1 \< 65% predicted, and
✓. FEV1/ FVC \< 70

Exclusion criteria

✕. The subject has a diagnosis of pulmonary arterial hypertension (PAH) or PH for reasons other than COPD as outlined in inclusion criterion 3. This would include, but is not limited to, the concomitant presence of thromboembolic disease (acute or chronic), untreated or inadequately treated obstructive sleep apnea, connective tissue disease (including but not limited to systemic sclerosis/scleroderma, or systemic lupus erythematosus), sarcoidosis, interstitial lung disease,human immunodeficiency virus-1 infection, and other conditions under WHO Group 1, 2, 4, and 5 classifications.
✕. The subject has received any Food and Drug Administration (FDA)-approved medication for the treatment of PAH (ie, prostacyclin, prostacyclin receptor agonist, endothelin receptor antagonist \[ERA\], phosphodiesterase type 5 inhibitor \[PDE5-I\],or soluble guanylate cyclase \[sGC\] stimulator) within 60 days of the first dose of study drug, except for acute vasoreactivity testing.
✕. The subject has evidence of clinically significant left-sided heart disease as defined by the following criteria per the most recent assessment:
✕. Left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) \>15 mmHg (or \>12 mmHg if pulmonary vascular resistance \[PVR\] ≥4 to \<6.25 WU)
✕. Left ventricular ejection fraction \<40% as assessed by either angiography or echocardiography.

What they're measuring

Incidence of Adverse Events Among Participants through 48 Weeks

Timeframe: 48 weeks

Trial details

NCT IDNCT03012646

SponsorUnited Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-04

View on ClinicalTrials.gov More Pulmonary Hypertension trials